Final analysis of the phase II PLATFORM trial in 266 patients with HER2-negative advanced oesophagogastric adenocarcinoma: maintenance capecitabine vs surveillance improved median PFS (5.0 vs 2.8 months; HR 0.69) but not OS; grade 3+ adverse events 46% vs 29%.
RCTn = 266
Gordon et al. Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial